PRP, Wharton's jelly, exosomes and amniotic products: comparing documentation by category

Four starting materials, one loose umbrella term

"Orthobiologics" is frequently used as a catch-all, but the four categories it covers are built from fundamentally different starting materials. Platelet-rich plasma (PRP) is drawn from the patient and concentrated at the point of care. Wharton's jelly products are manufactured allografts derived from donated umbilical cord tissue. Exosome preparations are extracellular vesicle (EV) products; request the specific source material for each one, such as a cultured cell line or cord blood. Amniotic-derived products come from placental or amniotic membrane and fluid tissue. Grouping all four under one label obscures how differently each one is sourced, processed and regulated.

A useful orthobiologics comparison separates three questions for each product: what is the raw material, what happens to it between collection and the vial, and which regulatory framework the supplier says applies. Marketing copy can blur these distinctions. A lot-specific certificate of analysis and a processing summary generally do not.

• PRP: autologous, prepared chairside from the patient's own blood draw
• Wharton's jelly: donor-derived perinatal tissue allograft, cryopreserved or lyophilized
• Exosomes/EVs: particle preparations from a cord-blood or cell-line source, liquid or lyophilized
• Amniotic-derived: membrane or fluid-derived allograft material

How each category is actually prepared

This site does not describe PRP preparation. Evaluate PRP documentation separately from PB's donated perinatal products. Wharton's jelly allografts begin with tissue recovered at a scheduled full-term delivery from a screened, consenting donor, then processed into a cryopreserved or lyophilized format carrying a unique lot identifier.

Request the exact source and processing description for each product. Bio Xsomes has a cord blood-origin hPESC source; Bio EX and Bio AER are umbilical cord-derived. Request the same detail for amniotic-derived products from their supplier.

Documentation needs differ by category. Request the applicable product, device or lot records for PRP equipment, and lot-specific records for allograft and EV products.

Regulatory classification is not the same across categories

Because PRP is autologous and minimally manipulated at the point of care, it is generally handled outside the human cell and tissue product (HCT/P) distribution framework altogether. Whether an intended use for a Wharton's jelly allograft meets all applicable criteria in 21 CFR 1271.10 is for the clinic and its counsel to determine. Evaluate other categories separately.

Exosome and other extracellular vesicle products sit in a different category. FDA has stated publicly that there are no FDA-approved exosome products. These preparations are generally regulated as biologic drugs under section 351, a different pathway than the section 361 framework. Purchase and clinical-use decisions for exosome products belong to the ordering physician and their own regulatory counsel. Amniotic-derived allografts raise the same 1271.10 question as Wharton's jelly products and require the same case-by-case review. None of this is legal advice; a distributor's description of its own regulatory posture is a starting point for due diligence, not a substitute for a clinic's own regulatory counsel.

These products are not FDA approved or licensed for any disease or condition. Information is for licensed healthcare professionals and is not medical or legal advice.

Documentation that makes an orthobiologics comparison meaningful

A documentation comparison is only useful if each category is backed by paper. For allograft categories (Wharton's jelly, amniotic-derived), that means a lot-specific certificate of analysis, a donor eligibility summary, and sterility and release-testing records tied to that lot. For exosome and EV products, that means characterization data: particle concentration, the isolation method used, and marker identification such as tetraspanin testing, reported using consistent terminology.

The Minimal Information for Studies of Extracellular Vesicles (MISEV2023) guidance recommends describing preparations as "extracellular vesicles" unless exosome-specific biogenesis has actually been demonstrated, and reporting source, size, concentration and markers rather than a single headline number. A particle count from one supplier is not directly comparable to another supplier's particle count unless the isolation and measurement methods match.

Where documentation comparisons commonly go wrong

One error is treating all four categories as variations on the same regulatory and compositional theme because they are marketed in similar language. Another is comparing a single headline specification, such as a particle count or protein concentration, across suppliers without checking whether the underlying test methods are the same. A third is accepting a supplier's regulatory label ("361-compliant," "research use only") as a settled fact rather than as a claim to verify against the clinic's own counsel and against FDA's own enforcement history for the category.

A sound internal comparison framework tracks sourcing, processing method, storage and handling requirements, available lot documentation, and the regulatory question each category raises. It should never include a claimed result.